Pfizer Partners with YaoPharma to Develop GLP-1 Obesity Drug

Pfizer Inc. +1.67% Pre

Pfizer Inc.

PFE

28.55

28.30

+1.67%

-0.88% Pre

Pfizer Inc. has announced an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical Group. The partnership focuses on the development, manufacturing, and commercialization of YP05002, a small molecule GLP-1 receptor agonist currently in Phase 1 development for chronic weight management. This collaboration is expected to strengthen Pfizer's pipeline in cardiometabolic diseases and advance its efforts in the obesity treatment market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251209536063) on December 09, 2025, and is solely responsible for the information contained therein.
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.